Profile data is unavailable for this security.
About the company
Physiomics PLC is a United Kingdom-based company, which provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology. The Company offer its services by utilizing its proprietary Virtual Tumour predictive software, industry standard tools (such as NONMEM and MATLAB), as well as developing bespoke models using the R programming language. Virtual Tumour is a predictive quantitative systems' pharmacology (QSP) model used worldwide by global pharmaceuticals to small biotech companies to support oncology Research and development (R&D). It is a semi-mechanistic model that incorporates an abstracted representation of the cell cycle, Deoxyribonucleic acid (DNA) damage/ repair and elements of the immune response. The Company is also developing its technology for use in the field of personalized medicine. The Company is focused on helping pharma and biotech clients.
- Revenue in GBP (TTM)543.25k
- Net income in GBP-609.35k
- Incorporated2001
- Employees11.00
- LocationPhysiomics PLCBee House140 Eastern Avenue, Milton ParkOXFORD OX14 4SBUnited KingdomGBR
- Phone+44 123 584 1575
- Fax+44 870 167 1931
- Websitehttps://www.physiomics.co.uk/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acceler8 Ventures PLC | 0.00 | -66.35k | 675.00k | 2.00 | -- | 21.87 | -- | -- | -0.0885 | -0.0885 | 0.00 | 0.0412 | 0.00 | -- | -- | 0.00 | -70.17 | -- | -103.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 70.16 | -- | -- | -- |
| Physiomics Plc | 543.25k | -609.35k | 1.37m | 11.00 | -- | 3.24 | -- | 2.52 | -0.0045 | -0.0045 | 0.004 | 0.0021 | 0.9904 | -- | 2.39 | 49,386.36 | -111.09 | -31.65 | -149.67 | -36.55 | -- | -- | -112.17 | -46.66 | -- | -- | 0.00 | -- | -9.06 | -5.45 | -27.68 | -- | -4.53 | -- |
| R8 Capital Investments PLC | 1.08m | -6.41m | 2.36m | 7.00 | -- | -- | -- | 2.18 | -0.0632 | -0.0632 | 0.0103 | -0.015 | 0.3074 | -- | 166.31 | 154,428.60 | -182.34 | -107.80 | -416.16 | -218.53 | 6.38 | 13.43 | -593.25 | -696.48 | 0.3795 | -107.33 | 20.28 | -- | -63.74 | -- | 86.17 | -- | -- | -- |
| Oxford Technology 2 Ventr Cptl Trst PLC | -1.33m | -1.58m | 4.10m | 0.00 | -- | 0.268 | -- | -- | -0.0569 | -0.0569 | -0.0478 | 0.2612 | -0.1796 | -- | -- | -- | -21.34 | -19.16 | -21.61 | -19.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | 8.03 | -- | 6.66 | -- | -- | -- |
| Orchard Funding Group PLC | 8.75m | 1.51m | 5.45m | 22.00 | 3.60 | 0.3004 | 3.51 | 0.6225 | 0.0709 | 0.0709 | 0.4097 | 0.8489 | 0.1486 | -- | 0.1773 | 397,590.90 | 2.57 | 3.62 | 5.98 | 7.72 | 70.15 | 77.73 | 17.30 | 23.72 | -- | -- | 0.6783 | 45.94 | 27.04 | 8.74 | 12.85 | 2.53 | 5.92 | 0.00 |
